Naorp :: Medicine :: Medical Specialties :: Ophthalmology (86)

Permanent Ophthalmology Jobs

Ophthalmology jobs
Wed, 08 Feb 2012 23:13:50 -0500
All Ophthalmology jobs for Wed Feb 8 2012
Ophthalmology jobs in "Fellowship trained Retinal specialist for a growing Ophthalmology Group" - IL
Tue, 20 Dec 2011 13:27:44 -0500
Job 9110525 Fellowship trained Retinal specialist for this growing Ophthalmology group in central Illinois Fellowship trained REtinal specialist needed for this growing group Call schedule as flexible
Ophthalmology jobs in "Ophthalmologists wanted to join an established practice in Nebraska" - NE
Tue, 20 Dec 2011 13:27:44 -0500
Job 94958 Come on board into a ready-made Ophthalmology practice Very lavished sign on bonus awaits interested and qualified specialist Competitive base income is in place This is an opportunity to practice

Archives of Ophthalmology current issue

The Cost-effectiveness of Welcome to Medicare Visual Acuity Screening and a Possible Alternative Welcome to Medicare Eye Evaluation Among Persons Without Diagnosed Diabetes Mellitus [Clinical Sciences]
Rein, D. B., Wittenborn, J. S., Zhang, X., Hoerger, T. J., Zhang, P., Klein, B. E. K., Lee, K. E., Klein, R., Saaddine, J. B. Mon, 09 Jan 2012 12:41:32 -0800
Objective  To estimate the cost-effectiveness of visual acuity screening performed in primary care settings and of dilated eye evaluations performed by an eye care professional among new Medicare enrollees with no diagnosed eye disorders. Medicare currently reimburses visual acuity screening for new enrollees during their initial preventive primary care health check, but dilated eye evaluations may be a more cost-effective policy. Design  Monte Carlo cost-effectiveness simulation model with a total of 50 000 simulated patients with demographic characteristics matched to persons 65 years of age in the US population. Results  Compared with no screening policy, dilated eye evaluations increased quality-adjusted life-years (QALYs) by 0.008 (95% credible interval [CrI], 0.005-0.011) and increased costs by $94 (95% CrI, –$35 to $222). A visual acuity screening increased QALYs in less than 95% of the simulations (0.001 [95% CrI, –0.002 to 0.004) and increased total costs by $32 (95% CrI, –$97 to $159) per person. The incremental cost-effectiveness ratio of a visual acuity screening and an eye examination compared with no screening were $29 000 and $12 000 per QALY gained, respectively. At a willingness-to-pay value of $15 000 or more per QALY gained, a dilated eye evaluation was the policy option most likely to be cost-effective. Conclusions  The currently recommended visual acuity screening showed limited efficacy and cost-effectiveness compared with no screening. In contrast, a new policy of reimbursement for Welcome to Medicare dilated eye evaluations was highly cost-effective.
Lack of Thrombospondin 1 and Exacerbation of Choroidal Neovascularization [Laboratory Sciences]
Wang, S., Sorenson, C. M., Sheibani, N. Mon, 09 Jan 2012 12:41:19 -0800
Objectives  To assess the impact of thrombospondin 1 (TSP1) deficiency on choroidal neovascularization (CNV) and to determine whether administration of a TSP1 antiangiogenic mimetic peptide attenuates CNV. Methods  The impact of TSP1 deficiency on laser-induced CNV was assessed using wild-type (TSP1+/+) and TSP1-deficient (TSP1–/–) mice. Three laser burns were placed in each eye of TSP1+/+ and TSP1–/– mice to induce CNV. Intravitreal injection of the TSP1 mimetic peptide was performed on days 1 and 7 postlaser in the mice. For quantitative measurements of neovascularization, intercellular adhesion molecule 2 staining was performed at 14 days postlaser of the choroidal-sclera flat mounts. The recruitment of macrophages to the sites of damage was investigated by immunohistochemistry. The CNV area was measured by intercellular adhesion molecule 2 staining and use of ImageJ software. Results  The TSP1–/– mice exhibited significantly larger areas of neovascularization on choroidal flat mounts compared with TSP1+/+ mice. This was consistent with enhanced recruitment of macrophages in TSP1–/– mice compared with TSP1+/+ mice 3 days postlaser. The development of CNV was significantly attenuated in mice receiving the TSP1 antiangiogenic mimetic peptide compared with those receiving vehicle alone. Conclusions  Deficiency of TSP1 contributes to enhanced choroidal neovascularization. This is consistent with the anti-inflammatory and antiangiogenic activity of TSP1. The TSP1 antiangiogenic peptide was effective in attenuation of CNV. Clinical Relevance  Intravitreal injection of TSP1 antiangiogenic mimetic peptides may provide alternative treatment for CNV.
Spectral-Domain Optical Coherence Tomographic Assessment of Severity of Cystoid Macular Edema in Retinopathy of Prematurity [Clinical Sciences]
Maldonado, R. S., O'Connell, R., Ascher, S. B., Sarin, N., Freedman, S. F., Wallace, D. K., Chiu, S. J., Farsiu, S., Cotten, M., Toth, C. A. Mon, 09 Jan 2012 12:41:08 -0800
Objective  To investigate whether the severity of cystoid macular edema (CME) in neonates who were 31 to 36 weeks' postmenstrual age, as viewed by spectral-domain optical coherence tomography (SD-OCT) imaging, predicts the severity of retinopathy of prematurity (ROP) or is related to systemic health. Design  Of 62 prematurely born neonates in a prospective institutional review board–approved study, 42 met the following inclusion criteria: at least 1 SD-OCT imaging session prior to 37 weeks' postmenstrual age and prior to ROP laser treatment, if a laser treatment was performed, and an ophthalmic ROP examination at or after 41 weeks' postmenstrual age, evidence of complete retinal vascularization in zone III, or documentation through telephone report of such information after transfer of care. Measures of CME severity, including central foveal thickness, retinal layer thicknesses, and foveal-to-parafoveal thickness ratio in 1 eye per subject, were compared with ROP outcomes: laser treatment, maximum plus disease, and maximum ROP stage. Systemic health factors were also correlated. Results  Cystoid macular edema was present in 50% of neonates. Multiple elongated cystoid structures within the inner nuclear layer were most common. The presence of CME was not associated with ROP outcomes. The central foveal thickness, the thickness of the inner retinal layers, and the foveal-to-parafoveal thickness ratio were higher in eyes that required laser treatment or that developed plus disease or ROP stage 3. Cystoid macular edema was not clearly associated with systemic factors. Conclusions  Cystoid macular edema is common in premature infants screened for ROP before 37 weeks' postmenstrual age, with the most common SD-OCT phenotype of a bulging fovea from multiple elongated cystoid spaces. Detection of CME is not associated with ROP severity; however, tomographic thickness measurements could potentially predict a higher risk of requiring laser treatment or developing plus disease or ROP stage 3. Systemic health factors are probably not related to the development of CME.

Subscribe to Ophthalmology RSS feed